Search

Displaying results 3411 - 3420 of 9714 in total
  1. Drug

    Basroparib

    go.drugbank.com/drugs/DB21582
    Investigational

    Basroparib has a monoisotopic molecular weight of 421.17 Da. … Basroparib is a small molecule drug. The usage of the INN stem '-parib' in the name indicates that Basroparib is a poly-ADP-Ribose polymerase inhibitor.

  2. Drug

    Gridegalutamide

    go.drugbank.com/drugs/DB21593
    Investigational

    Gridegalutamide has a monoisotopic molecular weight of 818.32 Da. … Gridegalutamide is a small molecule drug. The usage of the INN stem '-lutamide' in the name indicates that Gridegalutamide is a non-steroid antiandrogen.

  3. Drug

    Docirbrutinib

    go.drugbank.com/drugs/DB21606
    Investigational

    Docirbrutinib has a monoisotopic molecular weight of 578.24 Da. … Docirbrutinib is a small molecule drug. The usage of the INN stem '-brutinib' in the name indicates that Docirbrutinib is a agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitor.

  4. Drug

    Tamuzimod

    go.drugbank.com/drugs/DB21621
    Investigational

    Tamuzimod has a monoisotopic molecular weight of 545.0 Da. … Tamuzimod is a small molecule drug. The usage of the INN stem '-imod' in the name indicates that Tamuzimod is a immunomodulator, both stimulant/suppressive and stimulant.

  5. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    Lomedeucitinib has a monoisotopic molecular weight of 419.15 Da. … Lomedeucitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Lomedeucitinib is a Janus kinase inhibitor.

  6. Drug

    Bimokalner

    go.drugbank.com/drugs/DB21717
    Investigational

    Bimokalner has a monoisotopic molecular weight of 355.1 Da. … Bimokalner is a small molecule drug. The usage of the INN stem '-kalner' in the name indicates that Bimokalner is a opener of calcium-activated (maxi-K) K+-channel.

  7. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

  8. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … [A224474] One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA).

  9. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070] It is a precision-engineered graft composed of three cell populations isolated from an HLA-matched donor's mobilized peripheral blood — purified hematopoietic stem and progenitor cells (HSPCs) … [L64070,L64071] This composition is designed to improve survival free of chronic GVHD compared with a conventional transplant.

  10. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    Each domain comprises two separate sub-domains (A and B) [A40060]. … This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101].

    Products: UMAN ALBUMIN200G/L, ALBÚMINA HUMANA 200G/L